Hypericin
- Generic Name
- Hypericin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C30H16O8
- CAS Number
- 548-04-9
- Unique Ingredient Identifier
- 7V2F1075HD
- Background
Hypericin is under investigation for the treatment of Cutaneous T-cell Lymphoma.
- Associated Conditions
- -
- Associated Therapies
- -
Confirmatory Study of Topical HyBryte™ Vs. Placebo for the Treatment of CTCL
- Conditions
- Interventions
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Soligenix
- Target Recruit Count
- 80
- Registration Number
- NCT06470451
- Locations
- 🇺🇸
Medical Dermatology Specialists, Phoenix, Arizona, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸Therapeutics Clinical Research, San Diego, California, United States
HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
- Conditions
- Interventions
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Soligenix
- Target Recruit Count
- 10
- Registration Number
- NCT06149247
- Locations
- 🇺🇸
Rochester Skin Lymphoma Medical Group, Fairport, New York, United States
Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light
- Conditions
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Ellen Kim, MD
- Target Recruit Count
- 50
- Registration Number
- NCT05872854
- Locations
- 🇺🇸
Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
Topical SGX302 for Mild-to-Moderate Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Soligenix
- Target Recruit Count
- 47
- Registration Number
- NCT05442190
- Locations
- 🇺🇸
Therapeutics Clinical Research, San Diego, California, United States
PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Soligenix
- Target Recruit Count
- 9
- Registration Number
- NCT05380635
- Locations
- 🇺🇸
Rochester Skin Lymphoma Medical Group, Fairport, New York, United States
A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected Subjects
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 24
- Registration Number
- NCT00000792
- Locations
- 🇺🇸
Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States
🇺🇸Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
🇺🇸NY Univ. HIV/AIDS CRS, New York, New York, United States
A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 Lymphocytes
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 32
- Registration Number
- NCT00000645
- Locations
- 🇺🇸
Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States
🇺🇸University of Minnesota, ACTU, Minneapolis, Minnesota, United States
🇺🇸NY Univ. HIV/AIDS CRS, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.